Key result
Prophylactic treatment with bisoprolol preserved left ventricular ejection fraction (78% vs 71.09%) and attenuated doxorubicin-induced cardiotoxicity in rats.
Why the study?
Evidence is lacking for routine cardioprotective prophylaxis against doxorubicin cardiotoxicity in low-risk oncological patients, and the distinct roles of individual prophylactic medications required clarification.
Does prophylactic treatment with bisoprolol, perindopril, or eplerenone prevent doxorubicin-induced cardiotoxicity in a healthy rat model?
Population
Twelve-week-old male Wistar rats
Comparison
Bisoprolol vs perindopril vs eplerenone vs intravenous DOX alone vs saline
Design
Comparative experimental animal study
Follow-up
Two months after the last DOX administration
Authors
Loading...
Hypothesis-generating for prophylactic bisoprolol in doxorubicin cardiotoxicity; human trials needed before clinical consideration.
Does prophylactic treatment with bisoprolol, perindopril, or eplerenone prevent doxorubicin-induced cardiotoxicity in a healthy rat model?
Absolute Event Rate: 78% vs 71.09%
p-value: p=0.0357
Prophylactic bisoprolol or perindopril effectively mitigates doxorubicin-induced cardiotoxicity and improves survival in a healthy rat model.
Lódi et al. (2020) studied Doxorubicin-induced cardiomyopathy (n=45). Prophylactic bisoprolol, perindopril, or eplerenone vs. Doxorubicin only or saline was evaluated on Left ventricular ejection fraction at follow-up (p=0.0357). Prophylactic treatment with bisoprolol preserved left ventricular ejection fraction (78% vs 71.09%) and attenuated doxorubicin-induced cardiotoxicity in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: